| abstract |
The invention relates to anthranilic acids of formula (I) wherein the substituents R1-R3 have the designations cited in the claims. Said acids have no unwanted and detrimental salidiuretic properties, but rather very good cardioprotective properties, for example in terms of oxygen deficiency phenomena. Due to their pharmacological properties, said acids are highly suitable as cardioprotective pharmaceuticals for the prophylaxis and treatment of infarction, as well as the treatment of angina pectoris, also preventively inhibiting or strongly reducing the pathophysiological processes in the case of disorders caused by ischaemia. The protective action of the inventive compounds of formula (I) against pathological, hypoxic and ischaemic situations, and the inhibition of the cellular Na<+>/HCO3 cotransporter (NBC), enables said compounds to be used as pharmaceuticals for treating all acute or chronic disorders caused by ischaemia, or diseases induced in a primary or secondary manner by said disorders. |